local_hospital

SGS Belgium

Address
lock Available on a paid plan

Infectious Diseases and Vaccines

The research at SGS Belgium includes a strong focus on bacterial infections, virus diseases, and immune system diseases. Studies are looking at conditions such as chronic hepatitis B, chronic hepatitis D, influenza, respiratory syncytial virus infection, and human papilloma virus, with the goal of testing new vaccines and antiviral approaches, and improving protection against infection.

  • Chronic hepatitis B and chronic hepatitis D infection
  • Influenza and respiratory viral illness
  • Vaccine development and immune response research

Much of this work is designed to evaluate safety, immune activity, and how well new preventive or treatment strategies perform in people.

Respiratory and Allergy Research

This site is also active in respiratory tract diseases and related physiological processes, studying disorders such as asthma, chronic cough, non-cystic fibrosis bronchiectasis, pulmonary fibrosis, and asthma and COPD. The trials aim to assess new therapies and better understand symptom control, breathing outcomes, and treatment benefit.

  • Asthma and asthma-COPD overlap
  • Chronic cough and bronchiectasis
  • Pulmonary fibrosis and other lung conditions

Several studies at SGS Belgium are focused on whether new respiratory medicines are safe, well tolerated, and effective in everyday clinical use.

Metabolic, Liver, and Cardiovascular Studies

Clinical research here covers nutritional and metabolic diseases, cardiovascular diseases, and digestive system diseases. Main areas include obesity, overweight, hypercholesterolaemia, atherosclerosis, non-alcoholic steatohepatitis, metabolic dysfunction-associated steatohepatitis, and liver cirrhosis. The purpose is to test new treatment options and better understand disease progression.

  • Obesity and overweight
  • Cholesterol and atherosclerosis
  • Fatty liver disease and cirrhosis

These studies often explore whether investigational therapies can improve metabolic balance, liver health, and broader cardiometabolic outcomes.

Neurology, Immunology, and Rare Disease Research

The site conducts trials in nervous system diseases, immune system diseases, and congenital, hereditary, and neonatal diseases. Research includes Alzheimer’s disease, amyotrophic lateral sclerosis, multiple sclerosis, rheumatoid arthritis, atopic dermatitis, and Fragile X syndrome. The aim is to evaluate new therapies and improve understanding of difficult-to-treat conditions.

  • Alzheimer’s disease and ALS
  • Multiple sclerosis and inflammatory autoimmune disease
  • Rare genetic and immune-mediated disorders

At SGS Belgium, this area of research is centered on safety, symptom improvement, and potential disease-modifying benefit.

Women’s Health and Other Clinical Research

Additional trials address female urogenital diseases and pregnancy complications as well as broader clinical questions in healthy volunteers. Examples include sleep disturbances associated with menopause and studies in healthy participants designed to understand how new medicines move through the body and how they are tolerated. The goal is to support better treatment decisions and early evaluation of promising therapies.

  • Menopause-related sleep problems
  • Healthy volunteer safety and tolerability studies
  • Early assessment of new medicines and vaccines

This mix of research reflects the site’s broad clinical program, with work ranging from symptom-focused care to early testing of innovative treatments.

Site Overview

assignment
70
connected trials
corporate_fare
26
sponsors
science
15
IMPs

Activity Indicator

Last 6 months

8
Trials started
+300% vs previous period.
2
Trials started 6–12 months ago
70
Total trials linked
Highly Active
trending_upGrowing+300%
2
3
1
2
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status
lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years
lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
12
Sponsors (total)
26
Active sponsors
10

Sponsor Network

Top 10 by active trials.

lock +9 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

lock +6 more on a paid plan

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 307 other sites in Belgium

description
Trial volume
70
Outperforms 93% of sites
public
Therapeutic diversity
16areas
Outperforms 93% of sites
groups
Sponsor diversity
26sponsors
Outperforms 90% of sites

Therapeutic Area Benchmark — Belgium

Select a therapeutic area to compare against other sites in Belgium.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Belgium

Market Share

Country: Belgium

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in SGS Belgium

lock Showing 1 of 70 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
A Multiple Ascending Dose Study of MK-7480 in Healthy Participants for the Treatment of Non-Alcoholic SteatohepatitisMerck Sharp & Dohme LLCPhase INot RecruitingFeb 2024Jun 2024

IMP list

lock Showing 1 of 15 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Beclometasone Dipropionate1Unknown2023-08-032023-08-03

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.